Neurosteroid enantiomers as potentially novel neurotherapeutics
- PMID: 37085023
- PMCID: PMC10750765
- DOI: 10.1016/j.neubiorev.2023.105191
Neurosteroid enantiomers as potentially novel neurotherapeutics
Abstract
Endogenous neurosteroids and synthetic neuroactive steroids (NAS) are important targets for therapeutic development in neuropsychiatric disorders. These steroids modulate major signaling systems in the brain and intracellular processes including inflammation, cellular stress and autophagy. In this review, we describe studies performed using unnatural enantiomers of key neurosteroids, which are physiochemically identical to their natural counterparts except for rotation of polarized light. These studies led to insights in how NAS interact with receptors, ion channels and intracellular sites of action. Certain effects of NAS show high enantioselectivity, consistent with actions in chiral environments and likely direct interactions with signaling proteins. Other effects show no enantioselectivity and even reverse enantioselectivity. The spectrum of effects of NAS enantiomers raises the possibility that these agents, once considered only as tools for preclinical studies, have therapeutic potential that complements and in some cases may exceed their natural counterparts. Here we review studies of NAS enantiomers from the perspective of their potential development as novel neurotherapeutics.
Keywords: Allopregnanolone; Calcium channels; GABA(A) receptors; NMDA receptors; Neuroinflammation; Neuroprotection; Pregnanolone; Pregnenolone sulfate.
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Conflict of interest statement CFZ and JLM serve on the Scientific Advisory Board of Sage Therapeutics; DFC and CFZ have equity in Sage Therapeutics. The other authors have no conflicts to disclose.
Figures
References
-
- Alakoskela JM, Covey DF, Kinnunen PK, 2007. Lack of enantiomeric specificity in the effects of anesthetic steroids on lipid bilayers. Biochim. Biophys. Acta 1768, 131–145. - PubMed
-
- Althaus AL, Ackley MA, Belfort GM, Gee SM, Dai J, Nguyen DP, Kazdoba TM, Modgil A, Davies PA, Moss SJ, Salituro FG, Hoffmann E, Hammond RS, Robichaud AJ, Quirk MC, Doherty JJ, 2020. Preclinical characterization of zuranolone (SGE-217), a selective neuroactive steroid GABA-A receptor positive allosteric modulator. Neuropharmacol 181, 108333. 10.1016/j.neuropharm.2020. - DOI - PMC - PubMed
-
- Auchus RJ, Kumar AS, Boswell CA, Gupta MK, Bruce K, Rath NP, Covey DF, 2003. The enantiomer of progesterone (ent-progesterone) is a competitive inhibitor of human cytochromes P450c17 and P450c21. Arch. Biochem. Biophys 409, 134–144. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
